PROCEPT BioRobotics (NASDAQ:PRCT) EVP Alaleh Nouri Sells 6,892 Shares

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) EVP Alaleh Nouri sold 6,892 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $23.70, for a total transaction of $163,340.40. Following the completion of the transaction, the executive vice president owned 114,264 shares in the company, valued at approximately $2,708,056.80. This represents a 5.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

PROCEPT BioRobotics Price Performance

Shares of PRCT opened at $25.26 on Tuesday. The company has a market capitalization of $1.42 billion, a P/E ratio of -14.77 and a beta of 1.03. The company has a quick ratio of 5.77, a current ratio of 6.85 and a debt-to-equity ratio of 0.14. The firm has a 50 day moving average of $29.11 and a 200 day moving average of $32.83. PROCEPT BioRobotics Corporation has a twelve month low of $19.35 and a twelve month high of $66.85.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. The business had revenue of $76.38 million during the quarter, compared to the consensus estimate of $93.70 million. During the same period last year, the company posted ($0.35) earnings per share. The business’s revenue was up 11.9% compared to the same quarter last year. As a group, equities research analysts anticipate that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Oppenheimer reaffirmed a “market perform” rating on shares of PROCEPT BioRobotics in a research report on Thursday, February 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Thursday, January 22nd. Robert W. Baird assumed coverage on shares of PROCEPT BioRobotics in a research note on Friday. They set a “neutral” rating and a $30.00 target price on the stock. Truist Financial reduced their price target on shares of PROCEPT BioRobotics from $47.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Finally, Morgan Stanley decreased their price objective on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating for the company in a report on Tuesday, December 2nd. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $40.82.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Vega Investment Solutions increased its position in shares of PROCEPT BioRobotics by 52.0% during the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock valued at $45,000 after purchasing an additional 265 shares during the last quarter. JTC Employer Solutions Trustee Ltd purchased a new position in shares of PROCEPT BioRobotics in the third quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd grew its position in PROCEPT BioRobotics by 436.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after buying an additional 746 shares during the period. Center for Financial Planning Inc. purchased a new stake in PROCEPT BioRobotics during the fourth quarter valued at approximately $40,000. Finally, US Bancorp DE raised its position in PROCEPT BioRobotics by 175.7% in the third quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after acquiring an additional 1,079 shares during the period. 89.46% of the stock is owned by hedge funds and other institutional investors.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director Antal Rohit Desai completed a series of large open‑market purchases March 5–9, increasing his stake to 426,262 shares; the three Form 4 filings show roughly $10.5M of insider buying over those days — a strong bullish signal that executives view the stock as undervalued. Insider Purchase Filings
• Positive Sentiment: Research coverage was initiated at Robert W. Baird, which can increase visibility and trading interest (Baird’s note content/rating not included in the filing). Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Two senior executives (EVPs Kevin Waters and Alaleh Nouri) sold small stakes (6,721 and 6,892 shares respectively on March 6) for a combined ~13.6k shares (~$322k), likely personal liquidity rather than a company signal given the scale relative to the director’s purchases. Kevin Waters Sale Filing Alaleh Nouri Sale Filing
• Negative Sentiment: Two law firms (Levi & Korsinsky and Schall) announced securities‑fraud investigations related to PROCEPT’s prior guidance and statements (citing prior revenue targets and handpiece pricing comments). Such investigations raise the risk of litigation, distraction and potential disclosures or restatements — a clear negative catalyst for sentiment. Levi & Korsinsky Investigation Notice Schall Law Firm Investigation Notice

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.